rifapentine and moxifloxacin — Competitive Intelligence Brief

rifapentine and moxifloxacin (rifapentine and moxifloxacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fluoroquinolone. Area: Infectious Diseases.

phase 3 fluoroquinolone DNA-dependent RNA polymerase, DNA gyrase, topoisomerase IV Infectious Diseases Small molecule

Target snapshot

rifapentine and moxifloxacin (rifapentine and moxifloxacin) — Centers for Disease Control and Prevention. Rifapentine is a bactericidal antibiotic that inhibits DNA-dependent RNA polymerase, while moxifloxacin is a bactericidal antibiotic that inhibits DNA gyrase and topoisomerase IV.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rifapentine and moxifloxacin TARGET	rifapentine and moxifloxacin	Centers for Disease Control and Prevention	phase 3	fluoroquinolone	DNA-dependent RNA polymerase, DNA gyrase, topoisomerase IV
Baxdela	DELAFLOXACIN	Melinta	marketed	Fluoroquinolone Antibacterial		2017-01-01
Avelox	moxifloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	marketed	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Levaquin	Levofloxacin	Santen	marketed	Fluoroquinolone Antibacterial [EPC]	Multidrug and toxin extrusion protein 1	1996-01-01
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Cipro	Ciprofloxacin	Alk Abello	marketed	Fluoroquinolone	DNA gyrase	1987-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-04-21 — Cipro · 11369566 · Formulation · US
• 2029-04-21 — Cipro · 9603796 · Compound · US
• 2029-04-21 — Cipro · 9205048 · Method of Use · US
• 2029-12-11 — Cipro · 9233068 · Formulation · US
• 2030-04-27 — Cipro · 8318817 · Method of Use · US
• 2035-07-01 — Cipro · 9220796 · Formulation · US
• 2037-11-12 — Cipro · 11040004 · Method of Use · US
• 2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (fluoroquinolone class)

1. Centers for Disease Control and Prevention · 1 drug in this class
2. Dr. Reddy's Laboratories Limited · 1 drug in this class
3. UMC Utrecht · 1 drug in this class